← Back to headlines
Travere Outlines 2026 Growth and FSGS Milestone
Travere Therapeutics has outlined its growth strategy driven by FILSPARI and a new milestone in FSGS research for 2026.
20 Feb, 01:15 — 20 Feb, 01:15
ℹOnly 1 source covers this story
Read at source (1 outlet)
Related Stories
Investment Outlook: Dividend Aristocrats Poised for 2026 Rebound
13m ago
Stock Market Today, Feb. 20: CoreWeave Falls After Blue Owl Data Center Financing Failure Raises Funding Concerns
53m ago
Why CoreWeave Was Plunging To End the Week Today
53m ago
Costco Price Target Raised by Evercore ISI and Citi After Q2 Beat
53m ago